Lung cancer treatment advances, Myeloma and PCOS on CureTalks in October
October 25, 2021

Lung Cancer Mutations and Treatment Advances

with Dr. Kevan Shokat and Dr. Trever Bivona
Oct 5, 2021, 6:30 PM EST

Lung cancer, the most common cancer type with the highest mortality, can largely be categorized by the genetic mutations that cause it. By targeting the specific genetic mutation behind a patient’s cancer, targeted therapies have enabled increasing numbers of patients to experience fewer toxic side effects and, often, live free of disease following their treatment. KRAS mutations, which are found in about one-quarter of solid tumors are the leading cause of lung cancer driving the growth of about 25,000 new lung cancers each year. However, in spite of being discovered four decades ago, they were deemed ‘undruggable’, until earlier this year when FDA approved the first targeted therapy for lung cancer caused due to the KRAS mutation. We are talking to Dr. Kevan Shokat and Dr. Trever Bivona on lung cancer mutations, new treatments, trials and more. Lung cancer patient advocates Terri Conneran and Lisa Goldman join the panel to bring in the patient perspectives.  


Dr Kevan Shokat
Dr Trever Bivona 
Terri Conneran
Lisa Goldman
Priya Menon
Oct 26, 2021, 3:00 pm EST
Birth control pills or oral contraceptive pills (OCP) can be used for long-term treatment in women with PCOS who are not planning pregnancy. These pills have been shown to help regulate many PCOS symptoms such as irregular periods, extra hair growth and acne. However, due to the association of PCOS with metabolic syndrome, there is a controversy regarding the risks versus benefits of birth control pills in women with PCOS. Many women experience various side effects as well as withdrawal effects of birth control pills. Dr Carolyn Alexander of Southern California Reproductive Center will help us understand the science behind use of birth control pills in PCOS treatment, the risks and benefits involved, and other alternatives touching upon recent research in hormone combinations more effective in PCOS management. PCOS patients advocates Lisa Rosenthal and Tatiana Alafouzo will guide the discussion from the patient panel.

Dr Carolyn Alexander
Lisa Rosenthal
Tatiana Alafouzo
Shweta Mishra
Sep 8, 2021, 3:15 pm EST
The multiple myeloma treatment field has undergone several changes over the past 10-20 years. The average overall survival has changed from 1-3 years to 10-20 years. Yet, there is no established curative therapy for multiple myeloma. However, advanced monitoring with minimal residual disease (MRD) testing, targeted imaging, and cutting-edge molecular profiling of residual disease post-therapy will drive the field forward in the coming few years. With better identification of residual disease as well as detection of early recurrences, patients can look forward to improved remission-free follow-ups. Multiple myeloma survivor and advocate, Gary Petersen talks to world renowned multiple myeloma specialist Dr. Carl Ola Landgren as part of the CureTalks with Gary series. Gary discusses the goals and challenges of developing a best of class patient-focused myeloma center of excellence with Dr. Landgren. Dr Landgren was recently appointed the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Dr. Landgren, who was Chief of Myeloma Service for the past 6 years at Memorial Sloan Kettering Cancer Center, will also serve as Chief of the Myeloma Program at Sylvester.

Dr Carl Ola Landgren
Gary Petersen
Subscribe to CureTalks YouTube channel here.
Our Picks
TrialX Editor